ArticleMethods in molecular biology (Clifton, N.J.)2022
Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients.
Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- From Molecules to Models: miRNAs and Advanced Human Platforms of Neurodegeneration and Repair in Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Astrocytes in Primary Familial Brain Calcification (PFBC): Emphasis on the Importance of Induced Pluripotent Stem Cell-Derived Human Astrocyte Models.Advances in experimental medicine and biology · 2025Review
- Embryoid body-based differentiation of human-induced pluripotent stem cells into cells with a corneal stromal keratocyte phenotype.BMJ open ophthalmology · 2024Article
- Somatic Cell Reprogramming for Nervous System Diseases: Techniques, Mechanisms, Potential Applications, and Challenges.Brain sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The patient-derived iPSC lines provide valuable resources as these cells can be utilized to generate human cell types relevant to the disease of interest. In this context, human iPSC-based model systems are particularly useful for neurological diseases as the neuron and glial cell types affected by such diseases are difficult to obtain. Multiple sclerosis is a demyelinating central nervous system disease characterized by inflammation and eventually axonal damage. iPS cells generated from MS patients may allow for unique approaches for studying the disease in a species-specific manner, with a potentially limitless supply of patients' own glial and neuronal cells differentiated from the iPSCs. Here we describe the detailed protocol for establishing iPSCs from peripheral blood mononuclear cells that we have utilized to model multiple sclerosis. We particularly focused on optimized and cost-effective procedures using the integration-free Sendai virus-based reprogramming method for the generation and characterization of MS iPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.